🇺🇸 FDA
Pipeline program

RJMty19 (CD19-CAR-DNT cells)

RJMty19-B-NHL002

Phase 1 mab active

Quick answer

RJMty19 (CD19-CAR-DNT cells) for B-cell Non-Hodgkin's Lymphoma is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
B-cell Non-Hodgkin's Lymphoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials